NKMAX, Final Patient Dosed in Korean Clinical Trial... "Follow-up Observation Begins"

[Asia Economy Reporter Hyunseok Yoo] NKMAX announced on the 29th that it plans to begin follow-up observation after administering SuperNK (SNK01), a combination clinical trial with Keytruda, to the 18th and final patient in the Korean Phase 1/2a clinical trial of SuperNK (SNK01).

The clinical trial is a Phase 1/2a study conducted on 18 patients with stage 4 non-small cell lung cancer who failed first-line platinum-based standard treatment, aiming to confirm the safety at different doses and preliminary potential efficacy of SuperNK (SNK01) combined with Keytruda (generic name: pembrolizumab, pembrolizumab).

The follow-up observation period after administering the drug to the last patient is one year, with official clinical trial completion and results announcement scheduled for the first half of 2021.

NKMAX confirmed through some data from this clinical trial that the combination with Keytruda reduces side effects and has a synergistic effect, and submitted an abstract on this to ASCO 2020 (American Society of Clinical Oncology), where it was selected for a poster oral presentation.

Detailed results can be viewed on the ASCO 2020 webpage from May 29 (U.S. time) to June 2.

This content was produced with the assistance of AI translation services.